Preview

FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology

Advanced search

Pharmacoeconomic analysis of using benralizumab for treatment of severe asthma in inpatient and outpatient settings

https://doi.org/10.17749/2070-4909/farmakoekonomika.2022.143

Abstract

Objective: evaluation of the pharmacoeconomic feasibility of using benralizumab in the form of autoinjector (pen-injector device) in outpatient facilities compared with its use in the form of a syringe in hospital settings for the treatment of severe asthma (SA).

Material and methods. The cost minimization and budget impact analysis methods were used. The current practice of treating patients with SA with benralizumab in hospital settings at the expense of compulsory medical insurance funds was compared with the simulated practice. The simulated price was calculated as half patients receiving benralizumab in the hospital transferred to outpatient facilities at the expense of regional funds for 3 years. Direct medical costs included drug cost and outpatient patient monitoring services cost.

Results. The direct medical costs associated with benralizumab therapy in outpatient facilities were lower than the costs required for benralizumab therapy in the hospital settings and amounted to 0.99 million rubles versus 1.17 million rubles per one patient per year, respectively. Thus, the use of benralizumab in outpatient facilities leads to savings of 185 thousand rubles (16%). In 2021, 93 patients were prescribed benralizumab in hospital settings. The expansion of the application of benralizumab use in outpatient facilities will lead to a reduction in medical costs in the first year of therapy (when switching 16.7% of patients) by 5.9 million rubles (4,9%). The consistent expansion of the practice of benralizumab use in outpatient facilities over a 3-year horizon (when switching 50% of patients) will lead to a reduction in medical costs by 46.6 million rubles (12.1%).

Conclusion. Expansion of benralizumab use in outpatient facilities with a new form of autoinjector (pen-injector device) will lead to savings in medical costs and reduce the burden on the health care system, thus it is economically feasible.

About the Authors

M. V. Zhuravleva
Scientific Centre for Expert Evaluation of Medicinal Products; Sechenov University
Russian Federation

Marina V. Zhuravleva – Dr. Med. Sc., Deputy Director, Center of Clinical Pharmacology; Professor, Chair of Clinical Pharmacology and Propaedeutics of Internal Diseases. Scopus Author ID: 55878917900; RSCI SPIN-code: 6267-9901

8 bldg 2 Petrovskiy Blvd, Moscow 127051
8/2 Trubetskaya Str., Moscow 119991



S. N. Avdeev
Sechenov University; Research Institute of Pulmonology, Federal Medical and Biological Agency of Russia
Russian Federation

Sergey N. Avdeev – Dr. Med. Sc., Corresponding Member of RAS, Professor, Chair of Pulmonology; Head of Clinical Department. Scopus Author ID: 57220391293; RSCI SPIN-code: 1645-5524

8/2 Trubetskaya Str., Moscow 119991
28 Orekhovyy Blvd, Moscow 115682



Yu. V. Gagarina
Sechenov University
Russian Federation

Yulia V. Gagarina – MD, Assistant Professor, Chair of Clinical Pharmacology and Propaedeutics of Internal Diseases

8/2 Trubetskaya Str., Moscow 119991



T. V. Marin
Sechenov University
Russian Federation

Tatiana V. Marin – MD, PhD, Associate Professor, Chair of Clinical Pharmacology and Propaedeutics of Internal Diseases

8/2 Trubetskaya Str., Moscow 119991



References

1. Clinical guidelenes. Bronchial asthma. 2021. Available at: https://raaci.ru/dat/pdf/allergic_rhinitis.pdf (in Russ.) (accessed 25.05.2022).

2. Avdeev S.N., Nenasheva N.M., Zhudenkov K.V., et al. Prevalence, morbidity, phenotypes and other characteristics of severe bronchial asthma in Russian Federation. Pulmonologiya / Russian Pulmonology. 2018; 28 (3): 341–58 (in Russ.). https://doi.org/10.18093/0869-0189-2018-28-3-341-358.

3. Levy M.L. The national review of asthma deaths: what did we learn and what needs to change? Breathe (Sheff). 2015; 11 (1): 14–24. https://doi.org/10.1183/20734735.008914.

4. Kniajeskaia N.P., Anaev E.K., Kameleva A.A., et al. Targeted therapy in bronchial asthma. Benralizumab: focus on patients using systemic glucocorticosteroids. Meditsinskiy sovet / Medical Council. 2020; 17: 9–16 (in Russ.). https://doi.org/10.21518/2079-701X-2020-17-9-16.

5. 2022 GINA Report, Global Strategy for Asthma Management and Prevention. Available at: https://ginasthma.org/gina-reports/ (accessed 25.05.2022).

6. State Register of Medicines. LP-005492. Fasenra ® (benralizumab). Available at: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=ffb40ac9-9880-4f8e-b47b-b0bb71c7c974&t= (in Russ.) (accessed 25.05.2022).

7. Bleecker E.R., FitzGerald J.M., Chanez P., et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with highdosage inhaled corticosteroids and long-acting beta2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet. 2016; 388 (10056): 2115–27. https://doi.org/10.1016/S0140-6736(16)31324-1.

8. FitzGerald J.M., Bleecker E.R., Nair P., et al. Benralizumab, an antiinterleukin-5 receptor alpha monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016; 388 (10056): 2128–41. https://doi.org/10.1016/S0140-6736(16)31322-8.

9. Busse W.W., Bleecker E.R., FitzGerald J.M., et al. Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial. Lancet Respir Med. 2019; 7 (1): 46–59. https://doi.org/10.1016/S2213-2600(18)30406-5.

10. Korn S., Bourdin A., Chupp G., et al. Integrated safety and efficacy among patients receiving benralizumab for up to 5 years. J Allergy Clin Immunol Pract. 2021; 9 (12): 4381–92.e4. https://doi.org/10.1016/j.jaip.2021.07.058.

11. Resolution of the Government of the Russian Federation of 30.07.1994 No. 890 “On state support for the development of the medical industry and improving the provision of medicines and medical products to the population and healthcare institutions”. Available at: https://base.garant.ru/101268/ (in Russ.) (accessed 25.05.2022).

12. Decree of the Government of the Russian Federation of 12.10.2019 No. 2406-r “On approval of the list of vital and essential medicines for medical use for 2020, the list of medicines for medical use, including medicines for medical use prescribed by decision of medical commissions of medical organizations, the list of medicines intended to provide persons with hemophilia, cystic fibrosis, pituitary nanism, Gaucher's disease, as well as a minimum range of medications, necessary for the provision of medical care”. Available at: https://base.garant.ru/72861778/ (in Russ.) (accessed 25.05.2022).

13. IQVIA Reports Second-Quarter 2021 Results and Raises Full-Year 2021 Guidance. Available at: https://www.iqvia.com/newsroom/2021/07/iqvia-reports-second-quarter-2021-results-and-raises-full-year-2021-guidance (accessed 25.05.2022).

14. Avdeev S.N., Emelyanov A.V., Kurbacheva O.M., et al. A new delivery device for benralizumab (autoinjector, pen-injector device) in the clinical practice of treating severe eosinophilic asthma: Conclusion of the Expert Council. Pulmonologiya / Russian Pulmonology. 2021; 31 (6): 776–81 (in Russ.). https://doi.org/10.18093/0869-0189-2021-31-6-776-781.

15. Martin U.J., Fuhr R., Forte P., et al. Comparison of autoinjector with accessorized prefilled syringe for benralizumab pharmacokinetic exposure: AMES trial results. J Asthma. 2019; 58 (1): 93–101. https://doi.org/10.1080/02770903.2019.1663428.

16. Ferguson G.T., Cole J., Aurivillius M., et al. Single-use autoinjector functionality and reliability for at-home administration of benralizumab for patients with severe asthma: GRECO trial results. J Asthma Allergy. 2019; 12: 363–73. https://doi.org/10.2147/JAA.S224266.

17. Federal State Statistics Service. Demographics. Population size and composition. Available at: https://rosstat.gov.ru/folder/12781 (in Russ.) (accessed 25.05.2022).

18. Chuchalin A., Khaltaev N., Antonov N.S., et al. Chronic respiratory diseases and risk factors in 12 regions of the Russian Federation. Int J Chron Obstruct Pulmon Dis. 2014; 9 (1): 963–74. https://doi.org/10.2147/COPD.S67283.

19. Avdeev S.N., Nenasheva N.M., Zhudenkov K.V., et al. Prevalence, morbidity, phenotypes and other characteristics of severe bronchial asthma in Russian Federation. Pulmonologiya / Russian Pulmonology. 2018; 28 (3): 341–58 (in Russ.). https://doi.org/10.18093/0869-0189-2018-28-3-341-358.

20. Nenasheva N.M. A difficult word “compliance”, or How to increase adherence to treatment for bronchial asthma. Astma i allergiya / Asthma and Allergies. 2013; 2: 15–9 (in Russ.).

21. Hekking P.W., Wener R.R., Amelink M., et al. The prevalence of severe refractory asthma. J Allergy Clin Immunol. 2015; 135 (4): 896–902. https://doi.org/10.1016/j.jaci.2014.08.042.

22. Sergeeva G.R., Emelyanov A.V., Korovina O.V., et al. Clinical profile of patients with severe asthma. Meditsinskiy sovet / Medical Council. 2015; 16: 46–9 (in Russ.). https://doi.org/10.21518/2079-701X-2015-16-46-49.

23. Letter of the Ministry of Health of the Russian Federation of 04.02.2022 No. 11-7/I/2-1631 “On methodological recommendations on ways to pay for medical care at the expense of compulsory medical insurance”. Available at: https://www.mgfoms.ru/document/160 (in Russ.) (accessed 25.05.2022).

24. PharmCompass. Regions of the RF® . Available at: https://aston-health.com/ensuring-market-access/pharmcompass/ramsar-regions-of-the-russian-federation.html (in Russ.) (accessed 25.05.2022).

25. Resolution of the Government of the Russian Federation of 28.12.2020 No. 2299 “On the Program of state guarantees of free medical care to citizens for 2021 and for the planning period of 2022 and 2023”. Available at: https://base.garant.ru/400165890/ (in Russ.) (accessed 25.05.2022).

26. Resolution of the Government of the Russian Federation of 28.12.2021 No. 2505 “On the Program of state guarantees of free medical care to citizens for 2022 and for the planning period of 2023 and 2024”. Available at: https://base.garant.ru/403335795/ (in Russ.) (accessed 25.05.2022).

27. Ermolaeva A.D., Krysanova V.S., Ermolaeva T.N., et al. Medical care payment improvement within diagnosis-related groups of patients with severe asthma requiring biologic disease-modifying drugs by regional adaptation mechanism in the Moscow Region. FARMAKOEKONOMIKA. Sovremennaya farmakoekonomika i farmakoepidemiologiya / FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. 2021; 14 (2): 151–66 (in Russ.). https://doi.org/10.17749/2070-4909/farmakoekonomika.2021.093.

28. Federal Antimonopoly Service. Information on decisions taken by the subjects of the Russian Federation to change the maximum sizes of wholesale and retail allowances to the actual selling prices set by manufacturers of medicines for medicines included in the list of VED, as well as on the subjects of the Russian Federation that have not made such decisions as of May 4, 2022. Available at: https://fas.gov.ru/documents/687916 (in Russ.) (accessed 25.05.2022).


Review

For citations:


Zhuravleva M.V., Avdeev S.N., Gagarina Yu.V., Marin T.V. Pharmacoeconomic analysis of using benralizumab for treatment of severe asthma in inpatient and outpatient settings. FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. 2022;15(2):175-186. (In Russ.) https://doi.org/10.17749/2070-4909/farmakoekonomika.2022.143

Views: 306


ISSN 2070-4909 (Print)
ISSN 2070-4933 (Online)